Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.5699
-0.0301 (-5.02%)
At close: Jan 29, 2026, 4:00 PM EST
0.5601
-0.0098 (-1.72%)
After-hours: Jan 29, 2026, 4:19 PM EST
Nexalin Technology Employees
Nexalin Technology had 6 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$26,155
Profits / Employee
-$1,446,485
Market Cap
10.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 6 | 0 | - | 6 | 0 |
| Dec 31, 2023 | 6 | 0 | - | 6 | 0 |
| Dec 31, 2022 | 6 | -4 | -40.00% | 6 | 0 |
| Jun 30, 2022 | 3 | 1 | 50.00% | 3 | 0 |
| Mar 31, 2022 | 10 | 6 | 150.00% | 2 | 8 |
| Dec 31, 2021 | 10 | 6 | 150.00% | 2 | 8 |
| Sep 30, 2021 | 2 | -2 | -50.00% | 2 | 0 |
| Dec 31, 2020 | 4 | - | - | 4 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Vivos Therapeutics | 109 |
| Lifeward | 80 |
| Beyond Air | 61 |
| Intelligent Bio Solutions | 55 |
| PAVmed | 39 |
| Movano | 32 |
| Tenon Medical | 27 |
| Sintx Technologies | 20 |
NXL News
- 15 days ago - Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD - GlobeNewsWire
- 2 months ago - Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program - GlobeNewsWire
- 2 months ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4 - GlobeNewsWire
- 2 months ago - Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity - GlobeNewsWire
- 2 months ago - Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel - GlobeNewsWire
- 3 months ago - Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia - GlobeNewsWire
- 3 months ago - Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel - GlobeNewsWire
- 3 months ago - Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies - GlobeNewsWire